News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Backing Away From Biotechs



10/19/2005 5:12:43 PM

The news flow in the biotech sector is beginning to slow down, while safety concerns in the pharmaceutical industry continue to dominate headlines. Standard & Poor's Equity Research downgraded the biotech industry this week to "neutral" from "positive," citing delays in drug filings and increased regulatory scrutiny. The research firm has "concerns over options expensing in second half of 2005" and recommends a more cautious approach to the sector. The American Stock Exchange Pharmaceutical Index (DRG) ended the week up 1.5%, while the Nasdaq Biotechnology Index (NBI) reversed last week's spirited gains with a decline of 2.5%.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES